chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride - Profile

« Back to Dashboard

What are the generic sources for chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride and what is the scope of patent protection?

Chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride is the generic ingredient in two branded drugs marketed by Haleon Us Holdings and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Haleon Us Holdings	ADVIL ALLERGY AND CONGESTION RELIEF	chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride	TABLET;ORAL	022113-001	Dec 21, 2011		OTC	Yes	Yes
Haleon Us Holdings	ADVIL MULTI-SYMPTOM COLD & FLU	chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride	TABLET;ORAL	022113-002	Apr 28, 2017		OTC	Yes	Yes

Investment Scenario and Fundamentals Analysis for Chlorpheniramine Maleate, Ibuprofen, and Phenylephrine Hydrochloride

Last updated: February 5, 2026

What are the market sizes and growth prospects for these active ingredients?

Chlorpheniramine Maleate

• Market size projected at $650 million globally in 2023.
• Compound annual growth rate (CAGR) estimated at 4.1% through 2028.
• Used primarily in antihistamine formulations for allergic rhinitis and cold remedies.

Ibuprofen

• Estimated market value of $3.2 billion in 2023.
• Expected CAGR of 3.5% from 2023 to 2028.
• Widely used NSAID for pain, fever, and inflammation.

Phenylephrine Hydrochloride

• Market size approximately $850 million in 2023.
• Projected CAGR around 2.8% over the next five years.
• Mainly a decongestant in over-the-counter (OTC) cold and allergy medications.

How do supply chain and manufacturing dynamics influence the valuation?

Chlorpheniramine Maleate

• Synthesized through multi-step chemical processes; sensitive to raw material costs.
• Raw materials are primarily sourced from Chinese suppliers, with potential supply disruptions due to geopolitical issues or environmental regulations.

Ibuprofen

• Large-scale production established since the 1960s; well-understood synthesis processes.
• Key raw material—isobutylbenzene—produced in a concentrated supply chain, creating vulnerability to feedstock shortages.
• Several generic manufacturers operate at high efficiency, exerting price pressure.

Phenylephrine Hydrochloride

• Synthesis involves phenylethanolamine intermediates; raw materials are commodity chemicals with volatile prices.
• Several Chinese and Indian producers dominate the synthesis and supply chain, influencing cost stability.

What patent and regulatory landscapes affect potential for investment?

Chlorpheniramine Maleate

• Patents expired domestically; generic competition intensifies.
• Well-established regulatory pathway; FDA market approval is not required for generics.

Ibuprofen

• Patent expiration in most markets since early 2000s.
• Generic market dominance; regulatory barriers are minimal.
• New formulations (e.g., fast-release, topical) can offer differentiated market entry points.

Phenylephrine Hydrochloride

• Patents expired or are close to expiration in key markets.
• Challenges exist due to regulatory scrutiny over efficacy and safety—FDA has questioned phenylephrine’s oral efficacy as a decongestant.
• Potential for reformulation or alternative delivery methods to extend marketability.

How are competitive and pricing pressures shaping the market?

• High commoditization for all three active ingredients due to widespread generic manufacturing.
• Price erosion has been significant; for example, generic ibuprofen prices declined by over 30% over the past five years.
• Raw material costs, especially for phenylephrine and chlorpheniramine, have also impacted margins.

What are the key innovation and differentiation factors?

• Limited scope for innovation due to the age of these compounds.
• Differentiation may arise from formulation improvements, such as sustained-release tablets, combined formulas, or alternative delivery routes.
• Regulatory approval for new formulations or indications can open niche markets.

What are the strategic investment considerations?

• Market maturity: All three active ingredients operate in mature markets with high generic penetration.
• Pricing outlook: Downward pricing pressure continues; investments should focus on process efficiency and cost control.
• Supply stability: Geopolitical risks in raw material sourcing require diversification strategies.
• Regulatory landscape: Changes in regulatory policies, especially concerning efficacy claims for phenylephrine, could impact future sales.
• Patent expiration: No significant patent protections remain; R&D investments should target formulation or delivery innovations for differentiation.

Summary table of key factors

Ingredient	Market Size (2023)	CAGR (2023-2028)	Patent Status	Major Raw Material Risks	Key Use/Indication
Chlorpheniramine Maleate	$650 million	4.1%	Expired domestically	Raw material supply disruptions from China	Allergic rhinitis, cold remedies
Ibuprofen	$3.2 billion	3.5%	Expired	Feedstock shortages, price competition	Pain, fever, inflammation
Phenylephrine Hydrochloride	$850 million	2.8%	Expiring/Expired	Price volatility of commodity chemicals	OTC decongestant

Key takeaways

• The global markets for chlorpheniramine maleate, ibuprofen, and phenylephrine hydrochloride are mature with modest growth.
• Patent expirations have intensified generic competition, applying downward pressure on prices.
• Raw material supply chain risks, especially for phenylephrine and chlorpheniramine, demand supply diversification strategies.
• Innovation focus centers on formulation improvements and delivery methods rather than new chemical entities.
• Regulatory environments may influence future market dynamics, notably for phenylephrine.

Frequently Asked Questions

1. What are the main drivers of growth for these ingredients?
   Growing demand for OTC cold and allergy medications sustains steady market volumes. Market penetration in emerging markets also contributes to growth.

2. Are there significant regulatory hurdles for expanding use?
   For generic formulations, regulatory entry is relatively straightforward. However, reformulations or new indications require approval, especially if efficacy data are contested (e.g., phenylephrine).

3. How might raw material price fluctuations affect investment returns?
   Exposure to commodity chemicals introduces cost volatility. Vertical integration or raw material sourcing diversification can mitigate risks.

4. What opportunities exist for differentiation?
   Development of controlled-release formulations, combination therapies, or alternative delivery methods can unlock niche markets.

5. What should investors monitor regarding patent status and regulation?
   Patent expirations signal market commoditization; regulatory scrutiny, especially of efficacy claims, can influence future sales.

---

Sources:
[1] MarketsandMarkets, "OTC Drugs Market," 2023.
[2] Grand View Research, "NSAID Market," 2023.
[3] U.S. Food and Drug Administration, "Drug Approvals and Regulation," 2023.